Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Barbour

Showing results (251-260 of 296) with videos related to

Pageof 30
Sort By:
Kidney International|December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathySean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
Substance Abuse|February 22, 2022
Collaborative health systems ECHO: The use of a tele-education platform to facilitate communication and collaboration with recipients of state targeted response funds in PennsylvaniaS Kawasaki, G Hwang, K Buckner, et al.
Kidney International Reports|April 30, 2025
Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial CohortsSean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Nature Communications|June 22, 2018
C-terminal truncation of IFN-γ inhibits proinflammatory macrophage responses and is deficient in autoimmune diseaseAntoine Dufour, Caroline L Bellac, Ulrich Eckhard, et al.
Kidney International Reports|July 18, 2025
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287]Sean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Kidney International|May 29, 2020
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction ToolSean J Barbour, Mark Canney, Rosanna Coppo, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 12, 2024
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled TrialJonathan Barratt, Adrian Liew, See Cheng Yeo, et al.
JAMA Internal Medicine|April 14, 2019
Evaluating a New International Risk-Prediction Tool in IgA NephropathySean J Barbour, Rosanna Coppo, Hong Zhang, et al.
Nature Chemistry|February 13, 2023
Reversible transformations between the non-porous phases of a flexible coordination network enabled by transient porosityVarvara I Nikolayenko, Dominic C Castell, Debobroto Sensharma, et al.
Journal of the American Society of Nephrology : JASN|October 27, 2024
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA NephropathyJonathan Barratt, Sean J Barbour, Robert M Brenner, et al.
Pageof 30

Showing results (251-260 of 296) with videos related to

Sort By:
Pageof 30
Kidney International|December 24, 2025
A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathySean J Barbour, Michelle A Hladunewich, Michael L McCaleb, et al.
Substance Abuse|February 22, 2022
Collaborative health systems ECHO: The use of a tele-education platform to facilitate communication and collaboration with recipients of state targeted response funds in PennsylvaniaS Kawasaki, G Hwang, K Buckner, et al.
Kidney International Reports|April 30, 2025
Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial CohortsSean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Nature Communications|June 22, 2018
C-terminal truncation of IFN-γ inhibits proinflammatory macrophage responses and is deficient in autoimmune diseaseAntoine Dufour, Caroline L Bellac, Ulrich Eckhard, et al.
Kidney International Reports|July 18, 2025
Erratum to "Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts" [<i>Kidney International Reports</i> Volume 10, Issue 4, April 2025, Pages 1283-1287]Sean J Barbour, Rosanna Coppo, Jonathan Barratt, et al.
Kidney International|May 29, 2020
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction ToolSean J Barbour, Mark Canney, Rosanna Coppo, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 12, 2024
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled TrialJonathan Barratt, Adrian Liew, See Cheng Yeo, et al.
JAMA Internal Medicine|April 14, 2019
Evaluating a New International Risk-Prediction Tool in IgA NephropathySean J Barbour, Rosanna Coppo, Hong Zhang, et al.
Nature Chemistry|February 13, 2023
Reversible transformations between the non-porous phases of a flexible coordination network enabled by transient porosityVarvara I Nikolayenko, Dominic C Castell, Debobroto Sensharma, et al.
Journal of the American Society of Nephrology : JASN|October 27, 2024
Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA NephropathyJonathan Barratt, Sean J Barbour, Robert M Brenner, et al.
Pageof 30